Related references
Note: Only part of the references are listed.Shared principles in NF-κB signaling
Matthew S. Hayden et al.
CELL (2008)
A signal network involving coactivated NF-κB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas
Tin Lap Lee et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Systems biology-defined NF-kappa B regulons, interacting signal pathways and networks are implicated in the malignant phenotype of head and neck cancer cell lines differing in p53 status
Bin Yan et al.
GENOME BIOLOGY (2008)
Chemokines in tumor angiogenesis and metastasis
Seema Singh et al.
CANCER AND METASTASIS REVIEWS (2007)
Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer
Jay Friedman et al.
CLINICAL CANCER RESEARCH (2007)
A novel nuclear factor-κB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status
Tin Lap Lee et al.
CLINICAL CANCER RESEARCH (2007)
Role of activated nuclear factor-κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck
Clint T. Allen et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2007)
Targeting MEK induces myelorna-cell cytotoxicity and inhibits osteoclastogenesis
Yu-Tzu Tai et al.
BLOOD (2007)
Nuclear factor-κB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma
Clint Allen et al.
CLINICAL CANCER RESEARCH (2007)
Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells
Kensuke Kojima et al.
CANCER RESEARCH (2007)
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification
Takafumi Okabe et al.
CANCER RESEARCH (2007)
Nuclear factor-κ13 in development, prevention, and therapy of cancer
Carter Van Waes
CLINICAL CANCER RESEARCH (2007)
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma
Klaus Podar et al.
CANCER RESEARCH (2007)
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer
Peng Hou et al.
CLINICAL CANCER RESEARCH (2007)
Epithelial stem cells: Turning over new leaves
Cedric Blanpain et al.
CELL (2007)
Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs of p53, NF-kappaB and other signal transcription factors in head and neck squamous cell carcinoma
Bin Yan et al.
GENOME BIOLOGY (2007)
Nuclear factor-kappa B p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101
Jianming Duan et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Signaling through RAS-RAF-MEK-ERK: from basics to bedside
Armin Zebisch et al.
CURRENT MEDICINAL CHEMISTRY (2007)
Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
Rintaro Noro et al.
BMC CANCER (2006)
Maintenance of head and neck tumor gene expression profiles upon lymph node metastasis
Paul Roepman et al.
CANCER RESEARCH (2006)
Targeted therapy in advanced non-small cell lung cancer (NSCLC): Where do we stand?
Hatem A. Azim et al.
CANCER TREATMENT REVIEWS (2006)
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
Fred R. Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression
D. S. Basseres et al.
ONCOGENE (2006)
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting
John C. Sok et al.
CLINICAL CANCER RESEARCH (2006)
Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-κB signaling as characteristics of a high-risk head and neck squamous cell carcinoma
Christine H. Chung et al.
CANCER RESEARCH (2006)
Protein kinase casein kinase 2 mediates inhibitor-κB kinase and aberrant nuclear factor-κB activation by serum factor(s) in head and neck squamous carcinoma cells
Mng Yu et al.
CANCER RESEARCH (2006)
Epidermal growth factor receptor biology in head and neck cancer
Shailaja Kalyankrishna et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo
T. A. Navas et al.
LEUKEMIA (2006)
Nuclear factor-κB in cancer development and progression
Michael Karin
NATURE (2006)
Loss of transforming growth factor-β type II receptor promotes metastatic head-and-neck squamous cell carcinoma
Shi-Long Lu et al.
GENES & DEVELOPMENT (2006)
Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells
ST Nawrocki et al.
CANCER RESEARCH (2006)
Multiple robust signatures for detecting lymph node metastasis in head and neck cancer
P Roepman et al.
CANCER RESEARCH (2006)
Effects of a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines
HY Ruan et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2006)
Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas
TL Lee et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma
C Van Waes et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis
JL Boerner et al.
MOLECULAR CARCINOGENESIS (2005)
Histone deacetylase inhibitors: discovery and development as anticancer agents
PA Marks et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2005)
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
QB She et al.
CANCER CELL (2005)
A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma
CH Druzgal et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2005)
Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma
B Worden et al.
CANCER RESEARCH (2005)
Overexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis
PL Zhang et al.
MODERN PATHOLOGY (2005)
Expression of protein tyrosine kinases in head and neck squamous cell carcinomas
WM Ongkeko et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2005)
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
T Mitsudomi et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells
A Thelemann et al.
MOLECULAR & CELLULAR PROTEOMICS (2005)
Clinical proteomics: From biomarker discovery and cell signaling profiles to individualized personal therapy
KR Calvo et al.
BIOSCIENCE REPORTS (2005)
Biological significance of c-erbB family oncogenes in head and neck cancer
SJ Rogers et al.
CANCER AND METASTASIS REVIEWS (2005)
The development of proteasome inhibitors as anticancer drugs
J Adams
CANCER CELL (2004)
Inositol pentakisphosphate promotes apoptosis through the PI3-K/Akt pathway
E Piccolo et al.
ONCOGENE (2004)
Proteasome inhibitor PS-341, induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling
Y Yang et al.
CANCER SCIENCE (2004)
Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma
A Loercher et al.
CANCER RESEARCH (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy
RG Pomerantz et al.
SEMINARS IN ONCOLOGY (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors
Y Zhang et al.
RADIATION RESEARCH (2004)
Proteasome inhibitor PS-341 induces a apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells
A Fribley et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
PI3K/Akt and apoptosis: size matters
TF Franke et al.
ONCOGENE (2003)
Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation
MM Coombes et al.
ONCOGENE (2003)
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
SR Hingorani et al.
CANCER CELL (2003)
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays
S Nishizuka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process
Y Dai et al.
ONCOGENE (2003)
Activation of cutaneous protein kinase Cα induces keratinocyte apoptosis and intraepidermal inflammation by independent signaling pathways
C Cataisson et al.
JOURNAL OF IMMUNOLOGY (2003)
The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells
TR Johnson et al.
ONCOGENE (2003)
P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines
CR Bradford et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2003)
Acetylation of ReIA at discrete sites regulates distinct nuclear functions of NF-κB
LF Chen et al.
EMBO JOURNAL (2002)
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines
CC Bancroft et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial
M Ronson et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Expression of proangiogenic chemokine Gro 1 in low and high metastatic variants of Pam murine squamous cell carcinoma is differentially regulated by IL-1α, EGF and TGF-β1 through NF-κB dependent and independent mechanisms
E Loukinova et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Inhibitors of histone deacetylase as new anticancer agents
M Jung
CURRENT MEDICINAL CHEMISTRY (2001)
Duration of nuclear NF-κB action regulated by reversible acetylation
LF Chen et al.
SCIENCE (2001)
Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
PA Marks et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation?
SH Hong et al.
FASEB JOURNAL (2000)
Growth regulated oncogene-α expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism
E Loukinova et al.
ONCOGENE (2000)
Serum levels of vascular endothelial growth factor in patients with head and neck cancer
F Riedel et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2000)
Share Paper
